Monoclonal antibodies initiated the unprecedented breakthroughs in cancer immunotherapy and are rapidly evolving with multiple therapeutic platforms. One next generation strategy engineers' multivalent proteins that ligate single-chain variable fragments targeting cellular effectors, tumor-associated antigens and cytokines. These developing therapeutics target and regulate cellular effector bioactivity and significantly improve clinical outcomes.
from Cancer via ola Kala on Inoreader http://ift.tt/1WKpZqT
via IFTTT
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου